A330050F15Rik Inhibitors
Chemical inhibitors of A kinase anchor inhibitor 1 function predominantly by modulating the activity of protein kinase A (PKA), which is a critical enzyme in the signaling pathways that A kinase anchor inhibitor 1 regulates. H-89 and KT5720 are direct inhibitors of PKA, and their action results in the reduction of PKA-mediated phosphorylation events that A kinase anchor inhibitor 1 is intended to control. By inhibiting this phosphorylation, these chemicals directly impede the function of A kinase anchor inhibitor 1. Similarly, myristoylated PKI, a potent PKA inhibitor, operates by directly preventing the kinase activity of PKA, which subsequently obstructs the functional role of A kinase anchor inhibitor 1 in the modulation of PKA signaling pathways. St-Ht31P, on the other hand, disrupts PKA anchoring, which is a different approach to impede the interactions between PKA and A kinase anchor inhibitor 1, thereby inhibiting A kinase anchor inhibitor 1's function in PKA signaling.
Furthermore, Rp-8-Br-cAMPS and Rp-cAMPs, both cAMP analogs, competitively inhibit PKA by preventing its activation. This inhibition of PKA activation necessarily inhibits the function of A kinase anchor inhibitor 1 because of its role in PKA-regulated pathways. Additionally, while ML7, chelerythrine, Go 6983, LY294002, and Wortmannin do not target A kinase anchor inhibitor 1 directly, they can indirectly inhibit its function through their action on other kinases and enzymes that are part of or influence PKA signaling pathways. ML7 inhibits myosin light chain kinase, potentially affecting PKA pathway phosphorylation events indirectly, while chelerythrine and Go 6983 inhibit protein kinase C (PKC), potentially altering PKA-PKC signaling crosstalk. LY294002 and Wortmannin are PI3-kinase inhibitors, which can diminish the activation of PKA by acting upstream within the signaling cascade. Lastly, Compound 2 increases cAMP levels by inhibiting phosphodiesterase, which can lead to a saturation of PKA activation and effectively impede the regulatory role of A kinase anchor inhibitor 1 in PKA signaling. Through these diverse mechanisms, each chemical exerts an inhibitory effect on the function of A kinase anchor inhibitor 1, either by directly targeting the PKA interaction or indirectly by modulating related signaling pathways.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
KT 5720 | 108068-98-0 | sc-3538 sc-3538A sc-3538B | 50 µg 100 µg 500 µg | $138.00 $220.00 $972.00 | 47 | |
KT5720 is another inhibitor of protein kinase A and therefore can inhibit A kinase anchor inhibitor 1 by reducing phosphorylation events that A kinase anchor inhibitor 1 would typically regulate. By mitigating these kinase activities, KT5720 can be seen as inhibiting the function of A kinase anchor inhibitor 1. | ||||||
Rp-8-Br-cAMPS | 129735-00-8 | sc-3539A sc-3539 | 500 µg 1 mg | $250.00 $340.00 | 22 | |
Rp-8-Br-cAMPS is a cAMP analog that competitively inhibits the cAMP-dependent protein kinase A. Since A kinase anchor inhibitor 1 interacts with components of the PKA pathway, this compound would inhibit A kinase anchor inhibitor 1 by blocking the activation of PKA and therefore the downstream effects that A kinase anchor inhibitor 1 has on this pathway. | ||||||
Rp-cAMPS | 151837-09-1 | sc-24010 | 1 mg | $203.00 | 37 | |
Rp-cAMPs acts as a cAMP antagonist that can inhibit protein kinase A. Inhibition of PKA would subsequently inhibit the function of A kinase anchor inhibitor 1, which influences PKA activity through anchoring mechanisms. | ||||||
ML-7 hydrochloride | 110448-33-4 | sc-200557 sc-200557A | 10 mg 50 mg | $91.00 $267.00 | 13 | |
ML7 is known to inhibit myosin light chain kinase. Though not directly inhibiting A kinase anchor inhibitor 1, it inhibits the kinase activity within the cell, which could lead to reduced phosphorylation of targets of PKA, and thus indirectly inhibit the functional role of A kinase anchor inhibitor 1 in these pathways. | ||||||
Chelerythrine | 34316-15-9 | sc-507380 | 100 mg | $540.00 | ||
Chelerythrine is a potent inhibitor of protein kinase C. While not directly inhibiting A kinase anchor inhibitor 1, by inhibiting PKC, which can be part of cross-talk signaling pathways with PKA, chelerythrine can indirectly inhibit the functional role of A kinase anchor inhibitor 1 in these interconnected pathways. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $105.00 $299.00 $474.00 | 15 | |
Go 6983 is a broad-spectrum protein kinase C inhibitor. Similar to chelerythrine, by inhibiting PKC and therefore the potential cross-talk with PKA pathways, Go 6983 can indirectly inhibit the functional role of A kinase anchor inhibitor 1. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is an inhibitor of PI3-kinase. Though it does not directly inhibit A kinase anchor inhibitor 1, PI3-kinase is upstream of several kinase pathways, including PKA. By inhibiting PI3K, LY294002 can indirectly inhibit the functional role of A kinase anchor inhibitor 1 by reducing PKA pathway activation. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is also an inhibitor of PI3-kinase. By inhibiting PI3K, wortmannin can indirectly inhibit the functional role of A kinase anchor inhibitor 1 by diminishing the activation of downstream kinases including PKA, which A kinase anchor inhibitor 1 is known to interact with. | ||||||